

A Study Evaluating TRIV-509 in Atopic Dermatitis

NCT07167758

Status	RECRUITING
Phase	Phase 2
Sponsor	Triveni Bio
Enrollment	90 participants

Key Eligibility Criteria

Inclusion (2)

- Has Atopic Dermatitis.
- Has moderate to severe, active and symptomatic AD

Exclusion (2)

- Severe or uncontrolled medical conditions.
- Use of topical treatments, phototherapy, systemic immunosuppressives or immunomodulatory therapies, or immunomodulatory biologics, within stated washout periods.

Locations (44 total)

Triveni Bio Site #11, Fountain Valley, California, United States
Triveni Bio Site #4, San Diego, California, United States
Triveni Bio Site #44, New Haven, Connecticut, United States
... and 41 more locations